Journal of Cardiothoracic and Vascular Anesthesia · Oct 20, 2026
Effects of the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin on Perioperative Endothelial Function in Patients Undergoing Cardiac Surgery: An Exploratory Analysis of MERCURI-1
By Wang M, Li X, Snel LIP et al.
OBJECTIVE: To investigate whether short-term treatment with empagliflozin (EMPA) is associated with attenuation of endothelial dysfunction and cardiac injury in patients undergoing cardiac surgery. DESIGN: An exploratory study using samples from the open-label randomized MERCURI-1 study. SETTING: Academic university hospital. PARTICIPANTS: Adult patients undergoing cardiac surgery with cardiopulmonary bypass. INTERVENTIONS: Patients received 10 mg/d EMPA starting 3 days before surgery and continuing until 2 days postoperatively or received standard perioperative care. MEASUREMENTS AND MAIN RESULTS: Blood samples were collected at baseline (prior to EMPA therapy), on the day of surgery (before the first incision), and 1 day after surgery. Plasma biomarkers for endothelial activation (endothelin-1), vascular leakage (angiopoietin-2), glycocalyx degradation (syndecan-1), cardiac injury (Troponin I and NT-proBNP), and systemic inflammation (IL-6, IL-8, and CRP) were measured. In vitro, human cardiac microvascular endothelial cells were exposed to patient plasma, and endothelial permeability was assessed. Surgery-induced changes in biomarkers of endothelial activation and vascular leakage did not differ significantly between the EMPA and control groups. The adjusted between-group differences were 0.097 pg/mL for endothelin-1 (95% confidence interval [CI] -0.478 to 0.672, p = 0.735), -465 pg/mL for angiopoietin-2 (95% CI -2,355 to 1,426, p = 0.623), and 19,540 pg/mL for syndecan-1 (95% CI -10,016 to 49,095, p = 0.19). No significant differences were found for cardiac injury or inflammatory biomarkers. In vitro, endothelial resistance did not differ between the EMPA and control groups. CONCLUSIONS: In this exploratory substudy, no significant differences in endothelial activation, vascular leakage, cardiac injury, or inflammation between were found the EMPA and control groups. Given the limited sample size, smaller treatment effects cannot be excluded.
doi.org/10.1053/j.jvca.2026.10.020Open accessPubMed 42998912Interventions